Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters

Reuters03-31

Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters

Nanjing Leads Biolabs disclosed two preclinical cancer drug candidates accepted for poster presentation at 2026 AACR Annual Meeting in San Diego on April 17-22, 2026.
Data will be presented in the future on April 21, 2026 from 2:00 p.m. to 5:00 p.m. PT.
LBL-054 TDC showed strong anti-tumor activity in preclinical models with a tolerability profile that supported repeat dosing in non-human primates.
LBL-061 showed broad anti-tumor effects in preclinical studies with immune-activating features, supported by tolerability in non-human primates.
Update positions Leads Biolabs to advance its T cell engager-drug conjugate and bispecific ADC programs, supporting its strategy across antibody and ADC platforms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12082309), on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623304255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 16:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623304255","market":"nz","top_or_hot":-1,"title":"Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Nanjing Leads Biolabs disclosed two preclinical cancer drug candidates accepted for poster presentation at 2026 AACR Annual Meeting in San Diego on April 17-22, 2026.\n        </li>\n<li>\n          Data will be presented in the future on April 21, 2026 from 2:00 p.m. to 5:00 p.m. PT.\n        </li>\n<li>\n          LBL-054 TDC showed strong anti-tumor activity in preclinical models with a tolerability profile that supported repeat dosing in non-human primates.\n        </li>\n<li>\n          LBL-061 showed broad anti-tumor effects in preclinical studies with immune-activating features, supported by tolerability in non-human primates.\n        </li>\n<li>\n          Update positions Leads Biolabs to advance its T cell engager-drug conjugate and bispecific ADC programs, supporting its strategy across antibody and ADC platforms.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12082309), on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 16:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Nanjing Leads Biolabs disclosed two preclinical cancer drug candidates accepted for poster presentation at 2026 AACR Annual Meeting in San Diego on April 17-22, 2026.\n        </li>\n<li>\n          Data will be presented in the future on April 21, 2026 from 2:00 p.m. to 5:00 p.m. PT.\n        </li>\n<li>\n          LBL-054 TDC showed strong anti-tumor activity in preclinical models with a tolerability profile that supported repeat dosing in non-human primates.\n        </li>\n<li>\n          LBL-061 showed broad anti-tumor effects in preclinical studies with immune-activating features, supported by tolerability in non-human primates.\n        </li>\n<li>\n          Update positions Leads Biolabs to advance its T cell engager-drug conjugate and bispecific ADC programs, supporting its strategy across antibody and ADC platforms.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12082309), on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252160.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4zJN1s:1","article_id":"2623304255","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623304255","pubTimestamp":1774947327,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nanjing Leads Biolabs disclosed two preclinical cancer drug candidates accepted for poster presentation at 2026 AACR Annual Meeting in San Diego on April 17-22, 2026.Data will be presented in the future on April 21, 2026 from 2:00 p.m. to 5:00 p.m. PT.LBL-054 TDC showed strong anti-tumor activity in preclinical models with a tolerability profile that supported repeat dosing in non-human primates.LBL-061 showed broad anti-tumor effects in preclinical studies with immune-activating features, supported by tolerability in non-human primates.Update positions Leads Biolabs to advance its T cell engager-drug conjugate and bispecific ADC programs, supporting its strategy across antibody and ADC platforms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","09887":"维立志博-B","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK1161":"生物科技"},"translate_title":"南京领先生物实验室表示两种临床前癌症候选药物已被AACR 2026海报接受","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":0.9},"content_text":"Nanjing Leads Biolabs says two preclinical cancer drug candidates accepted for AACR 2026 posters\n    \n\n\n          Nanjing Leads Biolabs disclosed two preclinical cancer drug candidates accepted for poster presentation at 2026 AACR Annual Meeting in San Diego on April 17-22, 2026.\n        \n\n          Data will be presented in the future on April 21, 2026 from 2:00 p.m. to 5:00 p.m. PT.\n        \n\n          LBL-054 TDC showed strong anti-tumor activity in preclinical models with a tolerability profile that supported repeat dosing in non-human primates.\n        \n\n          LBL-061 showed broad anti-tumor effects in preclinical studies with immune-activating features, supported by tolerability in non-human primates.\n        \n\n          Update positions Leads Biolabs to advance its T cell engager-drug conjugate and bispecific ADC programs, supporting its strategy across antibody and ADC platforms.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260331-12082309), on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623304255","isCrawlerRequest":true}